ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 221 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q1 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,769 | +406.8% | 875,075 | +523.8% | 0.05% | +475.0% |
| Q2 2023 | $941 | +277.9% | 140,272 | +397.3% | 0.01% | +300.0% |
| Q1 2023 | $249 | -64.2% | 28,204 | -69.0% | 0.00% | -80.0% |
| Q4 2022 | $695 | -100.0% | 91,017 | -73.7% | 0.01% | -68.8% |
| Q3 2022 | $2,460,000 | +714.6% | 345,564 | +826.1% | 0.03% | +700.0% |
| Q2 2022 | $302,000 | -89.5% | 37,312 | -82.0% | 0.00% | -88.9% |
| Q1 2022 | $2,870,000 | +695.0% | 206,766 | +1505.7% | 0.04% | +800.0% |
| Q4 2021 | $361,000 | -43.7% | 12,877 | +18.8% | 0.00% | -33.3% |
| Q4 2020 | $641,000 | -51.5% | 10,843 | -60.2% | 0.01% | -77.8% |
| Q3 2020 | $1,323,000 | -74.7% | 27,214 | -74.8% | 0.03% | -80.0% |
| Q2 2020 | $5,221,000 | +1318.8% | 107,916 | +806.2% | 0.14% | +938.5% |
| Q3 2019 | $368,000 | -90.7% | 11,908 | -85.5% | 0.01% | -91.8% |
| Q2 2019 | $3,967,000 | – | 82,133 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $23,152,516 | 15.55% |
| BERYLSON CAPITAL PARTNERS, LLC | 289,726 | $2,213,507 | 6.45% |
| Matrix Capital Management Company, LP | 11,572,590 | $88,414,588 | 1.69% |
| Pier Capital, LLC | 1,012,401 | $7,734,744 | 1.27% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $229,151,929 | 1.15% |
| Eagle Health Investments LP | 607,860 | $4,644,050 | 1.07% |
| Triatomic Management LP | 130,805 | $999,350 | 0.84% |
| Aristotle Atlantic Partners, LLC | 1,880,567 | $14,367,532 | 0.80% |
| Senator Investment Group LP | 1,000,000 | $7,640,000 | 0.69% |
| ARK Investment Management | 9,201,245 | $70,297,512 | 0.61% |